Cardiovascular And Immunology AdvancementsMerck's developing cardiovascular portfolio, advancements in I&I through the Prometheus transaction, and partnership with Daiichi are likely to position the company to grow through its Keytruda LOE.
Oncology Portfolio PerformanceKeytruda continued its usual dominance, beating consensus estimates by +1% and contributing to an overall Oncology portfolio beat.
Vaccine Market ExpansionMRK is optimistic regarding Gardasil China approval for male vaccination, which could present a future growth opportunity.